Bio-Rad Laboratories BIO Debt and Equity Securities, Unrealized Gain (Loss)
Debt and Equity Securities, Unrealized Gain (Loss) at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss.
The official record: Bio-Rad Laboratories’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's debt and equity securities, unrealized gain (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's debt and equity securities, unrealized gain (loss)?
- Bio-Rad Laboratories (BIO) reported debt and equity securities, unrealized gain (loss) of $225.1M in Q4 2025.
- How has Bio-Rad Laboratories's debt and equity securities, unrealized gain (loss) changed year-over-year?
- Bio-Rad Laboratories's debt and equity securities, unrealized gain (loss) increased by 133.9% year-over-year, from -$664.2M to $225.1M.
- What is the long-term trend for Bio-Rad Laboratories's debt and equity securities, unrealized gain (loss)?
- Over 3 years (2022 to 2025), Bio-Rad Laboratories's debt and equity securities, unrealized gain (loss) has grown at a -44.2% compound annual growth rate (CAGR), from -$5.19B to $900.4M.
- What does debt and equity securities, unrealized gain (loss) mean?
- This metric captures the fluctuations in the fair value of investment portfolios held by the company, such as equity stakes in other firms. These gains or losses are often non-operating and can significantly impact reported net income without affecting cash flow. It reflects the volatility of the company's investment strategy.